首页> 外文期刊>Journal of Biopharmaceutical Statistics >Weighted Evidence Approach of Bridging Study
【24h】

Weighted Evidence Approach of Bridging Study

机译:衔接研究的加权证据法

获取原文
获取原文并翻译 | 示例
       

摘要

The ICH E5 Guidance facilitates the registration of medicine among ICH regions by recommending a framework for evaluating the impact of ethnic factors upon a medicine's effect. It further describes the use of bridging studies, when necessary, to allow extrapolation of foreign clinical data to a new region. Bridging studies are performed in a new region for medicines already approved in the original region. The conventional noninferiority criterion requires the treatment effect (adjusted for placebo) attained in the new region preserves a prespecified proportion of the treatment effect attained in the original region. Such a bridging criterion, however, is often impractical. Hsiao et al. (20075. Hsiao , C.-F. , Hsu , Y.-Y. , Tsou , H.-H. , Liu , J.-P. ( 2007 ). Use of prior information for Bayesian evaluation of bridging studies . Journal of Biopharmaceutical Statistics 17 : 109 - 121 .[Taylor & Francis Online], [PubMed], [Web of Science ®]View all references) proposed a Bayesian approach that borrows the strength of the original trial to establish the treatment effect in the bridging region through using a weighted prior distribution. The weight, however, is often difficult to prespecify. In this presentation, we consider the overall treatment effect by combining the weighted effects attained in the original and bridging regions. The maximum weight allowed to be placed on the estimate of bridging region in order to show a significant overall treatment effect represents the strength of the treatment effect in the bridging region. Regional approval will be evaluated either by comparing the weight estimate with the prespecified limit or by benefit-risk evaluation of the medicine. Sample size requirements for the approaches are derived. The simulation results of type I error rate and power for the proposed methods are given. An example illustrates the application of the proposed procedures.View full textDownload full textKey WordsBridging study, Noninferiority, Simultaneous test, Weighted evidence approachRelated var addthis_config = { ui_cobrand: "Taylor & Francis Online", services_compact: "citeulike,netvibes,twitter,technorati,delicious,linkedin,facebook,stumbleupon,digg,google,more", pubid: "ra-4dff56cd6bb1830b" }; Add to shortlist Link Permalink http://dx.doi.org/10.1080/10543406.2012.701580
机译:ICH E5指南通过推荐评估种族因素对药物效果的影响的框架,促进了ICH地区之间的药物注册。它进一步描述了在必要时使用桥接研究以允许将国外临床数据外推到新区域。在新区域中进行了桥接研究,以研究原始区域中已经批准的药品。常规的非劣效性标准要求在新区域中达到的治疗效果(针对安慰剂进行调整)保留在原始区域中达到的预定比例的治疗效果。然而,这种桥接标准通常是不切实际的。萧等。 (20075. Hsiao,C.-F.,Hsu,Y.-Y.,Tsou,H.-H.,Liu,J.-P.(2007)。使用先验信息进行桥梁研究的贝叶斯评估。生物制药统计学杂志17:109-121。[Taylor&Francis Online],[PubMed],[Web of Science®]查看所有参考文献)提出了一种贝叶斯方法,该方法借鉴了原始试验的优势来确立桥接的治疗效果。通过使用加权先验分布来确定区域。但是,重量通常很难预先确定。在本演示中,我们通过结合在原始区域和桥接区域中获得的加权效果来考虑总体治疗效果。为了显示出显着的总体治疗效果,允许在桥接区域的估计值上放置的最大重量表示桥接区域中处理效果的强度。通过将重量估算值与预先设定的限值进行比较,或者通过对药物的收益风险评估,来评估区域批准。得出了这些方法的样本量要求。给出了所提方法的I类错误率和功率的仿真结果。一个例子说明了所建议程序的应用。 Delicious,linkedin,facebook,stumbleupon,digg,google,更多”,发布号:“ ra-4dff56cd6bb1830b”};添加到候选列表链接永久链接http://dx.doi.org/10.1080/10543406.2012.701580

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号